Trailing-twelve-month (TTM) revenue is $1.67 Billion with a year-over-year growth of +10.79%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $394,185,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-28 |
| Q4 FY2025Period ended 2025-12-31 | $384,547,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-25 |
| Q1 FY2026Period ended 2026-03-31 | $392,911,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-05 |
| Q2 FY2026Period ended 2026-06-30 | $496,009,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-28 |
| TTM revenue | $1,667,652,000 |
Current P/S: $7,173,545,880 market capitalization ÷ $1,667,652,000 TTM revenue = 4.30x.
Market capitalization source: FMP quote. Quote observed 2026-10-05T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $496.01M.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T12:55:28.699Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Aristada And Aristada Initio | N/A | $275M | $302M | $328M | $346M | $370M |
| L Y B A L V I | N/A | $8M | $96M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Foreign Country Excluding Specified Country | $197M | $187M | $178M | $170M | $146M | $102M |
| IRELAND | $3M | $2M | $2M |
$1.67B
$1.67 Billion
+10.79%
vs. $1.51B a year ago (TTM)
+8.68%
5 Year compound annual growth rate
1 Year
+10.79%
3 Year
+4.48%
5 Year
+8.68%
10 Year
+9.59%
15 Year
+14.95%
20 Year
+11.38%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $1.48B | ($81.73M) | (5.25%) |
| 2024 | $1.56B | ($105.77M) | (6.36%) |
| 2023 | $1.66B | +$551.61M | +49.61% |
| 2022 | $1.11B | ($61.96M) | (5.28%) |
| 2021 | $1.17B | +$135.00M | +13.00% |
| 2020 |
TTM Growth
+10.79%
3-Year CAGR
+4.48%
5-Year CAGR
+8.68%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-10-06T12:55:28.699Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-10-05.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $192M |
| $280M |
| N/A |
| License | $1M | N/A | N/A | N/A | N/A | N/A |
|---|
| Manufactured Product And Royalty | $23M | N/A | N/A | N/A | N/A | $291M |
|---|
| Manufacturing Revenue | N/A | N/A | N/A | N/A | N/A | $46M |
|---|
| Product | N/A | $627M | $778M | $920M | $1.1B | N/A |
|---|
| Research And Development | $2M | N/A | N/A | N/A | N/A | N/A |
|---|
| Vivitrol | N/A | $344M | $379M | $400M | $457M | $468M |
|---|
| $1M |
| $754,000 |
| UNITED STATES | $839M | $984M | $932M | $1.5B | $1.4B | $1.4B |
|---|
| $1.04B |
| ($132.19M) |
| (11.29%) |
| 2019 | $1.17B | +$76.67M | +7.01% |
| 2018 | $1.09B | +$190.90M | +21.13% |
| 2017 | $903.37M | +$157.68M | +21.15% |
| 2016 | $745.69M | +$117.36M | +18.68% |
